CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 239 enrolled
Drug / intervention
18F-DCFPyLdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT04390880
NCT04390880Phase 2Completed
CompareCT.gov

IMPACT OF 18F-DCFPyL PET/CT ON INITIAL AND SUBSEQUENT TREATMENT STRATEGIES OF PATIENTS WITH PROSTATE CANCER (PROSPYL)

VA Greater Los Angeles Healthcare System·interventional·Posted May 18, 2020·Updated May 16, 2025

In Brief

A Phase 2 clinical trial evaluating 18F-DCFPyL for Prostate Cancer. Completed, enrolled 239 participants across 1 site.

Detailed Summary

The main purpose of this phase II trial study is to determine whether a positron emission tomography (PET)/computed tomography (CT) scan using 18F-DCFPyL affects the clinical management plan in Veterans. In this study, the management plan prior to and after 18F-DCFPyL PET/CT will be recorded by specific questionnaires and corresponding changes in management will be analyzed. The scan will be used to see how the disease has spread. Both the treatment strategies and probable disease outcomes as relevant to clinical endpoints will be assessed. This study is open to Veterans only.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsProstate Cancer
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
202120222023202420252026
First PostedMay 18, 2020
Enrollment StartApr 7, 2020
Primary CompletionAug 31, 2021
TodayJul 2, 2026
Enrollment to primary: 1.4 yearsPosted 6.1 years ago

Interventions

18F-DCFPyLdrug

Study participants will receive intravenous administration of 18F-DCFPyL and undergo a PET/CT imaging study. Patients may be reenrolled in the study, if 18F-DCFPyL PET/CT is performed for subsequent management decision.